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including circulating microRNAs are useful to
predict the survival of patients with gastric cancer
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Background: Circulating tumor cells (CTCs) are metastatic cells disseminated into the bloodstreams. They have
been proposed to monitor disease progression for decades. However, the prognostic value of CTCs in gastric
cancer (GC) remains controversial. We performed a meta-analysis to investigate the topic.
Methods: A systematic search was made for relevant studies in academic data bases, involving the Medline, Embase,
and Science Citation Index. Data on prognosis of GC patients, such as recurrence-free survival (RFS) and overall survival
(OS), were extracted when possible. The meta-analysis was performed with the random effects model and the pooled
hazard ratios (HRs) and their associated 95% confident intervals (95%CIs) were computed as effect measures.
Results: Twenty six studies (including 40 subgroups) with peripheral blood samples of 1950 cases from 10 countries
were included in the final analysis. The pooled results showed that GC patients with detectable CTCs (including
circulating miRNAs) had a tendency to experience shortened RFS (HR = 2.91, 95% CI [1.84-4.61], I2 = 52.18%, n = 10).
As for patient deaths, we found a similar association of CTC (including circulating miRNAs) presence with worse OS
(HR = 1.78, 95% CI [1.49-2.12], I2 = 30.71%, n = 30). Additionally, subgroup analyses indicated strong prognostic powers
of CTCs, irrespective of geographical, methodological, detection time and sample size differences of the studies.
Conclusions: Our meta-analysis shows that CTCs (including circulating miRNAs) can predict the survival of GC patients.
Large prospective studies are warranted to determine the best sampling time points, detection methods in
homogeneous patients with GC in the future.Background
Gastric cancer (GC) is a very common disease with the
highest rates of prevalence and mortality in East Asia [1].
Unfortunately, available routine tests including serum
protein markers are not efficient enough to early detect
GCs or predict metastases [2]. Most GCs are diagnosed
at an advanced rather than an early stage, leading to an
overall 5-year survival rate of below 30%.
Circulating tumor cells (CTCs) are metastatic cells in
blood, sheltering subsets with metastasis-initiating ability
[3]. They have attracted much attention not only because
of their easy accessibility but also for their superiority
over conventional tumor markers [4]. CellSearch system* Correspondence: gesurgery@163.com
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unless otherwise stated.(Veridix LLC) is the only platform cleared by the FDA
for CTC quantification in cancer patients. Based on the
platform, CTCs have been investigated and proposed for
many aspects of cancer management, such as monitoring
disease recurrence [5] and therapy responses [6,7], deter-
mining drug-selection strategies [8], and predicting the
survival of cancer patients [9,10].
Nevertheless, due to technical limitations on CTC
detection, there are no widely accepted methods. Many
of the major techniques, including reverse transcription-
polymerase chain reaction (RT-PCR) and the CellSearch
system, have been suspected of their abilities to identify
CTC components with down-regulated epithelial markers
generated from epithelia-mesenchyme transition (EMT).
In consideration of those drawbacks, a number of studies
are focused on developing antigen-independent devices
(i.e., micro-infiltration and negative depletion of leukocytes)
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by clinical samples.
CTCs are also crucial contributor and indicator for GC
[11]. Meanwhile, controversies still exist in the prognostic
role of CTCs for GC. We recently reviewed studies on
detection and clinical impact of CTCs in patients with GC
[11], and found that researchers had reported diverse
detection methods, tumor markers, sampling time points
and results for CTCs, which were inconsistent and some-
times difficult for readers to understand. With the aim to
investigate the prognostic values of CTCs and to interpret
the results of available studies statistically, we performed a
meta-analysis on the topic.
Methods
Search strategies and study selection
We made an extensive search in the Medline, Embase
and Science Citation Index for studies investigating the
prognostic value of CTCs in GC patients without time
and language restrictions. Terms, such as “circulating
tumor cells”, “blood”, “gastric cancer” and “prognosis”,
were jointly searched.
To yield potential relevant publications, we screened
the titles, abstracts and author information of studies we
collected. Researches would not be considered for detailed
assessment, unless they met the following inclusion
criteria: (1) studies should investigate the prognostic
significance of CTCs on GC patients with at less one
outcomes (i.e., OS and RFS), (2) the forms of CTCs were
tumor cells from blood mononuclear cells (MNCs), CTC-
related molecular derivatives from MNCs and plasma
rather than protein tumor markers in serum, and (3) stud-
ies from the same institutions were included to keep the
maximum information if they reported different markers
or applied different methods.
To legitimize studies for subsequent meta-analysis, we
assessed the full texts and references of relevant articles
(including reviews) with the following exclusion criteria:
(1) duplicated publications, (2) patients enrolled were
less than twenty, (3) studies on serum protein markers,
(4) no survival data or insufficient data to be extracted,
and (5) case reports, editorials, comments and letters
were excluded.
Data extraction
Two reviewers (Z-y Zhang and Z-l Dai) independently
extracted the data. Baseline characteristics recorded for
each eligible study were as follows: surname of the first
author, year of publication, country of origin, number
and median/mean age of patients analysed, follow-up
duration, TNM stage of included subjects, detection
method, markers to identify CTCs, sampling time, detec-
tion rate, endpoints and survival data. Disagreements
were resolved by discussion.Statistical approaches
To statistically assess the prognostic effects of CTCs on
the survival of GC, we extracted individual HRs and
associated 95%CIs when available. Otherwise, they were
estimated base on survival data or survival curves using
suggested methods by Parmar [12] and Tierney et al
[13]. In addition, when HRs were presented by both
univariate and multivariate analyses, the latter ones were
preferable because multivariate analyses also considered
possible confounding of exposure effects [14].
Generally, a HR >1 indicated a worse outcome of
patient with positive expression of CTCs. We pooled the
extracted HRs with generic inverse variance method
provided in the Comprehensive Meta-Analysis program
(version 2.2, Englewood, NJ, Biostat). Potential hetero-
geneity across the studies was illustrated by forest plots
[15]. The Cochrane’s Q statistic and I2 statistic were
computed to test the significance [16]. The random effects
model was used only when the tests were significant
(two-tailed P value ≤0.1, I2 > 50%) [17,18].
For studies with multiple arms (i.e., resectable and
unresectable groups) or multiple markers (each marker
within the study can define the positivity of CTCs), each
of the subgroups was considered an independent data
set. However, as for studies with multiple time points
(i.e., pre-therapy and intra/post-therapy detections), we
used data from pre-therapy samples in prior to intra/
post-therapy samples because those data were usually
dependent. To validate the priority, sensitivity analyses
were conducted by alternating with data on the other
time points. With regard to studies from the same insti-
tutions, sensitivity analyses by excluding all of them or
only keeping the latest study were performed to make
sure whether there was significant impact to destabilize
the overall effects. In the present study, circulating
miRNAs were treated as novel indicators of CTCs for
GC. However, considering microRNAs (miRNAs) were
not as specific as the other markers to indicate CTCs, we
made subgroup analyses and meta-regression to assess the
reliability and potential biases as well (see below).
The quality of the included studies was assessed with
the Newcastle-Ottawa Scale (NOS) for cohort studies
[19], which was recommended by the Cochrane Library
for observational studies. To test the reliability of our
results, we performed sensitivity analyses. The influences
of a particular study on the summary effects were
explored by calculating the combined HRs after ran-
domly removing one included study. Sensitivity tests
were also conducted by inclusion of metastatic tumors
and quantified with the Duval and Tweedie’s trim and
fill method [20].
Furthermore, subgroup analyses were made to explore
existing heterogeneity. Studies were stratified by country
of study origin, publication year, sample size, approaches,
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analyses were performed only when there were two or
more studies included in the subgroups. Univariate meta-
regression analyses (random effects) on the same factors
were implemented [21].
Lastly, we measured publication biases of the eligible
studies using funnel plots. Biases were statistically tested
by Begg’s and Egger’s methods [22]. Fail-safe numbers
were calculated. We also investigated the impact of the
publication year on the pooled results by cumulative
meta-analyses. All of the above mentioned methods in
the meta-analyses have followed the MOOSE Checklist
(See Additional file 1).
Results
Baseline characteristics
The comprehensive search was performed on 15th March
2014, yielding a total of 2538 results (See Additional files
2, 3, and 4). Among the results, 1963 studies were identi-
fied as non-English publications, duplicates and studies
out of the scope of the analyses. Another 334 publications
were reported as non-research articles. All of them were
therefore excluded for detailed assessment. The remaining
61 reports were thoroughly assessed, of which 26 studies
were legitimized into the final analyses (Figure 1).
The twenty six studies [23-48] with 1950 patients
were published between the year of 2005 and 2013
in ten countries, which were located in East Asia
[23,25,26,28-30,32,34,36,37,40-42,44-48] or other areas
[24,27,31,33,35,38,39,43]. The median patient no. per
study was 69 (range, 26 to 251). The sampling time
point reported more frequently was pre-therapy
[24,27,29,30,32-37,40-46,48] (before operations or chemo-
therapies, n = 18), compared to intra [25,26,28,31,34,38,39]
or post-therapy [23,47] (during or after operations as
well as chemotherapies, n = 9). Only one study reported
multiple time points including baseline, week-2 and
week-4 during therapies [34]. The methods mostly used
to detect CTCs were molecular techniques (n = 21),
including RT-PCR [23,24,26,29,31-33,35,36,38-40,42,44-47]
methylation-specific PCR (MSP) [43], RT-PCR enzyme
linked immunosorbent assay (RT-PCR ELISA) [30,37] and
high-throughput colorimetric membrane-array (HTCMA)
[25]. Meanwhile, cytological means (n = 5) such as the
CellSearch system [28,34,48], fluorescence-activated cell
sorting (FACS) [27] and immunocytochemistry (ICC)
[27,41] were also reported. The commonly investigated
markers were cytokeratin 18, 19, 20 (CK18/19/20),
carcinoembryonic antigen (CEA) and miRNAs. Of note,
unlike classic tumor markers, the expressions of miRNAs
were not restricted to epithelial cells but frequently altered
in malignant tumors including GC. Therefore, miRNAs
were only moderately sensitive and specific for CTC
detection (i.e., the sensitivity and specificity of miR-200c [39] were 65.4% and 100%, respectively). Besides,
more than one markers were reported in ten researches
with six [26,27,29,33,40,41] of them defining CTC events
as the positivity of any one marker. Another four studies
[25,28,34,42] considered CTC status to be positive only
when all markers were positive. The median detection rate
of CTCs irrespective of methods and time points was
50.0% (range, 10.8% to 98.6%). Of note, all eligible studies
only detected CTCs in peripheral blood. In summary, nine
researches reported RFS as an endpoint for GC patients
while twenty two reported OS with one [45] of them
presenting cancer-specific survival (CSS), which could
be considered a subset of OS logically. Additionally, five
studies provided both RFS and OS data. All essential
characteristics of included studies (Table 1) were care-
fully evaluated for the following analyses.
Overall effects
The tests demonstrated heterogeneity of included stud-
ies on RFS (I2 = 52.18%, p = 0.027) and OS (I2 = 30.71%,
p = 0.058), respectively. Therefore, we had to perform
the meta-analyses with random effects model. The pooled
results (Figure 2) showed that CTCs including circulating
miRNAs were an significant prognostic factor for GC
patients (RFS: HR = 2.91, 95% CI [1.84-4.61], n = 10;
OS: HR = 1.78, 95% CI [1.49-2.12], n = 30).
Subgroup analyses and meta-regression
To clarify the intra-study inconsistencies, we stratified
the included studies based on variables as shown in
Table 2. Heterogeneity was eliminated in subgroups by
exclusion of studies published before the year of 2010,
with comparable HRs but more precise CIs. Further-
more, the heterogeneity dropped to insignificant level in
meta-analyses on OS when studies were stratified by
country, sampling time and detection rate. Of note,
when one subgroup exclusively reported East Asia
patients, cytological methods, pre-therapy detection or
large patient numbers (above median), the HR was more
conspicuous compared with that of its paired subgroup.
Furthermore, both RT-PCR and the CellSearch systems
were demonstrated to be valid approaches to detect
CTCs in predicting patient survival. Studies with and
without miRNAs did not lead to significant changes in
the overall effects although it tended to yield consistent
results with the same marker type, suggesting a need for
standard markers to identify CTCs in future studies.
When the studies grouped by method and sampling
time simultaneously (see Additional file 5: Table S3),
the heterogeneity became unobvious in the RT-PCR
group of PFS and OS, indicating that sampling time
was an important source of inconsistency. Nevertheless,
the prognostic role of CTCs for RFS was not observed
in a subgroup of only three studies [23,38,39] without
Figure 1 Flowchart of study selection.
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69.09%). This might because that the follow-up period for
study by Ikeguchi et al. was very short (less than 24 months)
and the censored rate in the study by Stein et al. was
relatively high with significant loss of patient information.
The results of subgroup analyses were in accordance
with the meta-regression to quantify heterogeneity across
studies (Table 3). As for studies on RFS, only time point
of blood collection was significantly correlated with
intra-study variability (slope = 0.9260, P = 0.007). While,
the country of origin (slope = 0.2241, P = 0.004), time
point (slope = 0.2733, P = 0.014) and positive rate of CTCs
(slope = -0.0102, P = 0.010) contributed to heterogeneity
across studies on OS. Besides, it seemed that inclusion of
less specific miRNAs did not contribute to significantheterogeneity by meta-regression on RFS (p = 0.507) and
OS (p = 0.444) studies.
Quality assessment and sensitivity analyses
To test whether the results were stable with known
heterogeneity, we performed sensitivity analyses. Three
researches [28,33,34] were identified as low quality reports
(NOS score ≤4, see Additional file 5: Table S2). Sensitivity
analysis by excluding these low quality studies showed
that the pooled effects were stable (RFS: HR = 2.92, 95%
CI [1.69-5.04], I2 = 57.27%, n = 9; OS: HR = 1.51, 95% CI
[1.36-1.69], I2 = 18.03%, n = 27). When we evaluating
the impact of including studies from same institutions
[25,26,32,36,42,48] as stated above, the results only
changed slightly by retaining the latest reports [25,42]
Table 1 Baseline characteristics of eligible studies
ID [Name (Year)] Country Stage (UICC) Methods Time points Markers Positive rates n/N (%) Endpoints Hazard ratios Quality
Ikeguchi (2005) [23] Japan I-IV RT-PCR post-therapy CEA 25/55(45.5) RFS/OS data extrapolated High
Illert (2005) [24] Germany I-IV RT-PCR Pre-therapy CK20 15/41(36.6) OS(R0)a data extrapolated High
Pre-therapy CK20 13/29(44.8) OS(R2/UR)a data extrapolated
Wu (2006) [25] China I-IV HTCMA intra-therapy CK19/CEA/MUC1/hTERT 39/64(60.9) OS data extrapolated High
Uen (2006) [26] China I-IV RT-PCR intra-therapy c-MET 32/52(61.5) OS data extrapolated High
MUC1 37/52(71.2) OS data extrapolated
Noworolska (2007) [27] Poland I-IV FACS-ICC Pre-therapy CK8/18/19 31/57(54.4) OS data extrapolated High
Hiraiwa (2008) [28] Japan IV CellSearch intra-therapy EpCAM/CK8/18/19 15/27(55.6) OS data extrapolated Low
Koga (2008) [29] Japan I-IV RT-PCR Pre-therapy CK19 8/69(11.6) OS data extrapolated High
CK20 10/69(15.5) OS data extrapolated
Yie (2008) [30] China I-IV RT-PCR Pre-therapy survivin 12/26(46.2) RFS reported in text High
Bertazza (2009) [31] Italy I-IV RT-PCR intra-therapy survivin 69/70(98.6) OS reported in text High
Arigami (2010) [32] Japan I-IV RT-PCR Pre-therapy B7-H4 71/94(75.5) OS reported in text High
Kutun (2010) [33] Turkey I-IV RT-PCR pre-therapy CK19 24/50(48.0) OS data extrapolated Low
CEA 10/50(20.0) OS data extrapolated
Matsusaka (2010) [34] Japan I-IV CellSearch pre-therapy EpCAM/CK8/18/19 17/52(32.7) RFS/OS reported in text Low
intra-therapy wk2b EpCAM/CK8/18/19 7/51(13.7) RFS/OS reported in text
intra-therapy wk4b EpCAM/CK8/18/19 9/48(18.8) RFS/OS reported in text
Saad (2010) [35] Egypt I-IV RT-PCR pre-therapy CK18 15/30(50.0) RFS/OS reported in text High
Arigami (2011) [36] Japan I-IV RT-PCR pre-therapy B7-H3 48/95(50.5) OS reported in text High
Cao (2011) [37] China I-IV RT-PCR pre-therapy survivin 45/98(45.9) RFS reported in text High
Stein (2011) [38] Germany I-IV RT-PCR intra-therapy S100A4 32/64(50.0) RFS data extrapolated High
Ayerbes (2012) [39] Spain I-IV RT-PCR intra-therapy miR-200c 28/52(53.8) RFS/OS reported in text High
Wang (2012) [40] China I-IV RT-PCR pre-therapy miR-20a 34/65(52.3) OS reported in text High
miR-17-5p 33/65(50.8) OS reported in text
Ito (2012) [41] Japan I-IV ICC pre-therapy telomerase 41/65(63.1) OS data extrapolated High
Arigami (2013) [42] Japan I-IV RT-PCR pre-therapy STC2 43/93(46.2) OS reported in text High
Balgkouranidou (2013) [43] Greece I-IV MSP pre-therapy mSOX17 43/73(58.9) OS reported in text High
Kang (2013) [44] China I-IV RT-PCR pre-therapy hTERT 118/118(100) RFS/OS reported in text High
Komatsu (2013) [45] Japan I-IV RT-PCR pre-therapy miR-21 47/69(68.1) OS reported in text High
miR-17-5p 38/69(55.1) OS data extrapolated
miR-106a 53/69(76.8) OS data extrapolated

















Table 1 Baseline characteristics of eligible studies (Continued)
Lee (2013) [46] Korea I-IV RT-PCR pre-therapy mSEPT9 27/153(17.6) RFS data extrapolated High
Song (2013) [47] China I-IV RT-PCR post-therapy miR-21 51/103(49.5) OS data extrapolated High
Uenosono (2013) [48] Japan I-IV CellSearch pre-therapy EpCAM/CK8/18/19 16/148(10.8) OS(R)c reported in text High
16/148(10.8) RFS(R)c data extrapolated
62/103(61.8) OS(UR)c data extrapolated
Note. Refer to Additional file 5: Table S1 for detailed information.
Refer to the abbreviation section for detailed abbreviations.
aR0 resection and R2/unresectable groups.
bTwo weeks and four weeks after baseline.

















Figure 2 Forest plots of RFS (a) and OS (b) in GC patients.
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Table 2 Results of subgroup analyses on RFS and OS
Variables RFS OS
HR[95%CI] n I2 Pd HR[95%CI] n I2 Pd
Year >mediana
No 2.45[1.13-5.31] 4 78.87% 0.003 1.82[1.34-2.46] 15 45.79% 0.027
Yes 3.02[2.18-4.18] 6 0.00% 0.519 1.72[1.46-2.04] 15 0.00% 0.479
Country
East Asia 2.93[1.67-5.14] 7 66.13% 0.007 1.76[1.50-2.07] 21 18.48% 0.220
Non-East Asia 2.62[1.35-5.10] 3 0.00% 0.596 1.41[1.22-1.63] 9 39.70% 0.103
Methodology
Cytological 3.71[1.95-7.06] 2 42.92% 0.186 1.77[1.16-2.70] 5 54.00% 0.069
Molecular 2.64[1.52-4.59] 8 57.03% 0.023 1.54[1.37-1.72] 25 26.23% 0.114
Approach
RT-PCR 2.61[1.52-4.59] 8 57.04% 0.023 1.79[1.46-2.20] 24 29.30% 0.090
CellSearch 3.71[1.95-7.01] 2 42.92% 0.186 2.00[1.28-3.13] 3 64.90% 0.058
Others / / / / 1.04[0.46-2.34] 3 0.00% 0.564
Marker type
Non-miRNA 3.08[1.80-5.26] 9 56.48% 0.019 1.80[1.45-2.25] 22 41.33% 0.023
miRNA / / / / 1.70[1.33-2.16] 8 0.00% 0.602
Time point
Pre-therapy 3.45[2.54-4.67] 7 0.00% 0.529 1.81[1.54-2.13] 23 28.58% 0.100
Intra/post-therapy 1.09[0.25-4.73] 3 69.09% 0.039 1.38[1.19-1.60] 7 0.00% 0.539
Patient no. > medianb
No 2.40[1.24-4.65] 5 71.90% 0.007 1.73[1.44-2.08] 18 9.70% 0.339
Yes 3.24[2.26-4.66] 5 0.00% 0.482 1.82[1.37-2.42] 12 47.91% 0.032
Detection rate >medianc
No 2.69[1.33-5.44] 5 74.38% 0.004 1.75[1.42-2.15] 14 33.73% 0.105
Yes 2.82[1.87-4.27] 5 0.00% 0.524 1.49[1.31-1.70] 16 27.31% 0.149
Overall 2.91[1.84-4.61] 10 52.18% 0.027 1.78[1.49-2.12] 30 30.71% 0.058
aThe median year for both RFS and OS was 2010.
bThe median patient no. per study for RFS and OS was 59 and 65, respectively.
cThe median detection rate for RFS and OS was 46.05% and 51.55%, respectively.
dTwo-tailed P value of tests for heterogeneity.
Table 3 Results of meta-regression on RFS and OS
Variables RFS OS
Slope SEa P value Slope SEa P value
Year 0.1650 0.0854 0.053 0.0377 0.0340 0.267
Country −0.0101 0.5767 0.986 0.2241 0.1113 0.004
Method −0.4894 0.5604 0.382 −0.0180 0.2176 0.934
Marker type −0.2650 0.3991 0.507 0.1061 0.1386 0.444
Time point 0.9260 0.3442 0.007 0.2733 0.1115 0.014
Patient no. 0.0045 0.0061 0.465 −0.0011 0.0031 0.726
Detection rate −0.0206 0.0155 0.185 −0.0102 0.0020 0.010
aStandard error of the slope.
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OS: HR = 1.88, 95% CI [1.48-2.40], I2 = 42.07%, n = 24).
Further subgroup analyses and meta-regression did not
reach any significance in institution. Removing all of the 6
studies did not contribute to significant changes of the
pooled measures (OS: the same institution, HR = 1.55,
95% CI[1.23-1.96], n = 8, different institution, HR = 1.93,
95% CI[1.53-2.44], n = 22; RFS, different institution,
HR = 2.71, 95% CI [1.72-4.27], n = 9) although there
was a tendency that the 6 studies from the same popu-
lations were likely to present homogeneous results (OS,
same vs. different, I2 = 0.00% & P = 0.901 vs. I2 = 46.20%
& P = 0.010), indicating that future studies could benefit
from recruitment of homogeneous populations.
Moreover, conversions of statistical method to a fixed
effects model did not change the overall effects obviously
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CI [1.40-1.74]). Inclusion of the study [28] with single
stage IV subjects only yielded a very close result (OS:
HR = 1.78, 95% CI [1.49-2.12], I2 = 28.76%, p = 0.058). The
other analyses with removing one study (see Additional
file 6: Figures S1 and S2) and trim and fill method (see
Additional file 6: Figures S3 and S4) also indicated that
our results were stable.
Publication biases
Publication biases existed in OS group, as indicated by
Begg’s rank correlations (RFS: P = 0.721; OS: p = 0.193) and
Egger’s regression tests (RFS: P = 0.664; OS: p = 0.007).
We thus computed the fail-safe numbers for both (RFS:
n = 115; OS: n = 462). The calculations showed that only
when a minimum of 462 studies with negative results
were included, would the overall effects on OS be nega-
tive. Moreover, the year of publication (see Additional
file 6: Figures S5 and S6) did not led to any publication
bias according to cumulative meta-analyses.
Discussion
Our current meta-analysis provides strong evidence that
CTCs including circulating miRNAs in peripheral blood
are significantly associated with adverse RFS and OS of
GC patients, irrespective of the geographical, methodo-
logical, detection time and sample size differences.
In theory, CTCs take numerous advantages to be distinct-
ive markers in translational researches. But in practice,
the history of CTCs remains elusive and the detection
of CTCs still faces technical challenges. Previous inves-
tigations on breast and gastrointestinal cancers have
been meta-analysed [49-52] to elaborate some practical
problems. Here, we are focused on the prognostic sig-
nificance of CTCs in GC patients. Compared to another
two meta-analyses on the similar topic of GC [51,52],
we have applied many advanced statistical methods in
the present meta-analysis, such as “one study removed”,
trim and fill method, meta-regression, fail-safe numbers
as well as cumulative meta-analyses. These methods are
helpful to get deeper and more comprehensive insights
into the prognostic value of CTCs and potential hetero-
geneity of included studies.
There are some novel findings in our meta-analysis.
CTCs have shown significant utilities to prognose survival,
but it needs further clarification that which experimental
factors should be adjusted for accurate estimations of
survival benefits. Thus, we conducted subgroup analyses
by publication year, country, country, patient size, detec-
tion rate and marker type in addition to detection method
and time point. We found more pronounced HRs in some
studies, which exclusively reported East Asia patients,
cytological methods, pre-therapy CTC detection and large
study population. We further observed that studies tendedto be consistent if they were published after 2010, with
pre-therapy detections or higher detection rates. The
subgroup analyses also indicated considerable intra-
study heterogeneity caused by differences of geography,
sampling time and detection rate from included studies.
Through meta-regression, we finally confirmed and
quantified the extent of sampling time (0.926 for RFS
and 0.2733 for OS, respectively) which had positively
contributed to heterogeneity.
However, methodological differences were not signifi-
cant in both subgroup analyses and meta-regression.
Similar results were obtained from another meta-regression
which reported CTCs in breast cancer [50]. One possible
reason may be that both methods are antigen-dependent,
which enables them to detect some CTC subsets with prog-
nostic meanings. Nevertheless, the known tumor markers
used to identify CTCs also bring about a degree of bias,
for they are unable to recognize CTC subsets with down-
regulated markers (i.e., EMT cells). Besides, available
approaches to CTC detection have been questioned for
their low sensitivity and yields. Of note, our data sug-
gested that cytological identification of CTCs seemed to
be superior to molecular methods. It may be reasonable
because morphological examinations are more conserved
while it is easier for molecular techniques to give rise to
false positive results from non-neoplastic and contami-
nated samples. In spite of the heterogeneity from CTCs
phenotypes and methodology, employment of standard-
ized methods should be helpful to lower intra-study
inconsistencies.
Importantly, we observed remarkable heterogeneity from
time points of blood collection in groups of OS, with more
prominent HRs from pre-therapy detection. The CTC
detection rates of pre-therapy (RFS/OS: median = 45.90/
50.80%, mean = 33.60/49.20%) tended to be lower than
those of intra/post-therapy (RFS/OS: median = 45.50/
53.8%, mean = 37.41/54.30%) based on our included stud-
ies. It is believed that surgeries contribute to elevated
CTC detection rates shortly afterwards [53], and have
long-term effects on reduction of CTC burden and pro-
motion of survival in operable subjects. But it should
be noted that such promotion by surgical manipulations
tends to be associated with increased detectable levels of
CTC molecular derivatives, as is proved by a mouse model
[54]. Since molecular methods (i.e., RT-PCR) are unable
to recognize viable and functional CTCs, the detection
of CTCs immediately after surgeries may provide very
limited information to predict pathologic consequences
(i.e., distant metastases and deaths caused by cancer)
with this method. For instance, Ikeguchi et al. [23]
observed transient positive conversions of CTCs status
shortly after GC surgeries. But based on data collected
shortly after surgeries, the authors found that survival
of patients with detectable CTCs was better than those
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Therefore, it is at least improper to detect CTCs soon
after surgeries. Of cause, the differences in CTCs positive
rates in different time points are mainly because of the
long term anti-tumor treatments. CTCs can be eliminated
by chemotherapeutic drugs through direct and indirect
mechanisms, such as cytotoxic and antimetabolic effects.
Surgeries by excision of primary and metastatic tumors
directly stop the releasing of CTCs and cut off the bilateral
communications between CTCs and tumor masses. How-
ever, if cancers fail to be cured, CTCs may increase to high
levels as a result of tumor progression or recovery of
tumor cells from dormancy. In theory, CTC tests before
interventions contain baseline information of CTC burden.
Their presence at this time point actually indicates ongoing
or already established blood borne metastases, which
usually cannot be effectively controlled or thoroughly
eliminated. Since metastasis contributes to most cancer
deaths, it may be more pathologically meaningful to
characterize CTCs prior to any treatments. Consequently,
time point of blood collection should be an important
factor for researchers to estimate patient survival. But
post-therapy monitoring of CTCs at proper time points
is also very important because constantly increasing
CTC burden probably indicates tumor recurrences,
which will worsen patient survival if left untreated.
Some authors have concerned that baseline detection
have risks of failing to provide information about the
actual burden of CTCs after therapies thus might be
unable to accurately predict survival of patients post
treatments [49,55]. As few reports have investigated
multiple time points and most natural history of CTCs
remains elusive, the controversies on better time points
for CTC detection have not been well understood bio-
logically and pathologically. Further studies are needed
to expound whether there are significant differences
among different time points within the same patients
and whether patients can benefit from such differences.
We also noticed inconsistencies from the countries of
included patients in OS group. We pooled studies from
different populations, which usually resulted in non-
ignorable errors on total effects. But in our subgroup
analyses, the prognostic role of CTCs remained significant
regardless of regional differences. In addition, heterogen-
eity was observed from CTC detection rates. To a certain
extent, inconsistent detection rates may in turn reflect
heterogeneous populations, detection methods and time
points. As a result, large prospective studies are expected
to compare the impact of such differences on survival in
homogeneous GC patients.
It should be pointed out that there are some limita-
tions of our meta-analysis that allow us to interpret the
results with caution. We used data extracted from
heterogeneous studies, where individual patient datawere usually not available. The total number of patients
from retrievable data was relatively small. Large prospective
studies were absent for GC. Besides, there were only 10
eligible studies in the meta-analysis on RFS, of which the
results were limited. Although there was no standardized
tool to assess the quality of non-randomized and observa-
tional studies, the sensitivity analyses demonstrated that the
results were stable. To control biases generated by study
retrieval and data extraction, we had developed extensive
search strategies in advance to yield as much information
as possible by independent reviewers. We only included
studies with over 20 patients. To avoid data dredging, we
had presetted limited variables before meta-regression.
Although publication biases appeared in the study group
of OS, the estimation of fail-safe number confirmed no
obvious influences on our results.
Conclusions
In conclusion, our meta-analysis has evidenced the sig-
nificant prognostic power of CTCs including circulating
miRNAs for both RFS and OS in GC patients. Large
prospective studies are needed to validate the prognostic
values of CTCs with multiple time points in homogeneous
GC patients. But above all, bias-controlled markers and
standardized detection platforms are expected to normalize
and reduce the inconsistencies across studies.
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